藥物洗脫球囊導管市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

2024 年，全球藥物洗脫球囊導管市場價值為6.378 億美元，預計2025 年至2034 年複合年成長率為9.9%。對藥物洗脫球囊導管的偏好不斷增加。

冠狀動脈疾病、中風和周邊動脈疾病（PAD）等心血管疾病（CVD）已成為全球健康問題。影響因素包括不健康的生活方式、人口老化以及高血壓和糖尿病等疾病的普遍發生。這些因素導致對微創手術的需求激增，DEB 導管成為治療動脈阻塞和增強血流且無需永久性植入物的首選解決方案。

DEB 導管，也稱為藥物塗層球囊，在球囊擴張過程中將紫杉醇或西羅莫司等抗增殖藥物直接輸送到動脈壁。這種受控藥物釋放有助於治療增生並改善周邊血管和冠狀血管疾病的結果。市場依產品分為冠狀動脈疾病和周圍血管疾病 DEB 導管。 2024年，周邊血管疾病領域引領市場，創造了3.53億美元的收入。

周邊血管疾病 DEB 導管對於支架可能不適合的複雜病變特別有效。透過減少平滑肌細胞增生和防止再狹窄，這些導管可維持最佳血流並改善患者預後。由於恢復時間較短且併發症較少，人們對微創介入的偏好不斷增加，這極大地促進了 DEB 導管在周邊血管應用中的普及。

從材料來看，市場分為聚氨酯、尼龍和其他材料。基於聚氨酯的DEB 導管在2024 年產生2.254 億美元的收入，預計到2034 年將以10.4% 的複合年成長率成長。的血管結構中導航，確保患者舒適度，並降低手術過程中受傷的風險。

由於心血管和周邊動脈疾病入院人數增加，到 2024 年，醫院和診所將佔據最大的市場佔有率。由於對先進外科護理和微創干預的需求不斷成長，預計到 2034 年，該細分市場將達到 9.383 億美元。

就地區表現而言，北美地區在2024 年以2.722 億美元的收入佔據市場主導地位。 這一成長歸因於該地區先進的醫療基礎設施、CVD 的高患病率以及DEB 技術在介入性心臟病學和血管護理領域的廣泛採用。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 周邊疾病和心血管疾病的盛行率不斷上升
    • 藥物洗脫球囊導管的技術進步
    • 對微創手術的偏好日益增加
    • 老年人口不斷增加
  • 產業陷阱與挑戰
    • 產品成本高
    • 使用藥物洗脫球囊導管相關的感染風險
• 成長潛力分析
• 監管環境
• 報銷場景
• 技術景觀
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2034 年

• 主要趨勢
• 冠狀動脈疾病藥物洗脫球囊導管
  • 紫杉醇
  • 西羅莫司
• 周邊血管疾病藥物洗脫球囊導管
  • 紫杉醇
  • 西羅莫司

第 6 章：市場估計與預測：按材料分類，2021 - 2034 年

• 主要趨勢
• 聚氨酯
• 尼龍
• 其他材料

第 7 章：市場估計與預測：按最終用途，2021 - 2034 年

• 主要趨勢
• 醫院和診所
• 門診手術中心
• 導尿實驗室

第 8 章：市場估計與預測：按地區分類，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 9 章：公司簡介

• Aachen Resonance GmbH
• B. Braun
• Becton, Dickinson and Company
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Eurocor GmbH
• iVascular SLU
• Zhejiang Barty Medical Technology Co.Ltd
• Lepu Medical Technology(Beijing) Co. Ltd.
• MedAlliance
• Medtronic plc

The Global Drug-Eluting Balloon Catheters Market was valued at USD 637.8 million in 2024 and is projected to grow at a CAGR of 9.9% from 2025 to 2034. This expansion is primarily driven by the rising prevalence of peripheral and cardiovascular diseases, increasing preference for minimally invasive treatments, and the growing aging population worldwide.

Cardiovascular diseases (CVDs) such as coronary artery disease, strokes, and peripheral artery disease (PAD) have become a global health concern. Contributing factors include unhealthy lifestyles, aging populations, and the widespread occurrence of conditions like hypertension and diabetes. These factors have led to a surge in demand for minimally invasive procedures, with DEB catheters emerging as a preferred solution for managing arterial blockages and enhancing blood flow without the need for permanent implants.

DEB catheters, also known as drug-coated balloons, deliver antiproliferative drugs such as paclitaxel or sirolimus directly to the arterial walls during balloon expansion. This controlled drug release helps treat hyperplasia and improve outcomes in both peripheral and coronary vascular diseases. The market is segmented by product into coronary artery disease and peripheral vascular disease DEB catheters. In 2024, the peripheral vascular disease segment led the market, generating USD 353 million in revenue.

Peripheral vascular disease DEB catheters are particularly effective for complex lesions where stents may not be suitable. By reducing smooth muscle cell proliferation and preventing restenosis, these catheters maintain optimal blood flow and improve patient outcomes. The rising preference for minimally invasive interventions due to shorter recovery times and fewer complications has significantly contributed to the popularity of DEB catheters for peripheral vascular applications.

Material-wise, the market is categorized into polyurethane, nylon, and other materials. Polyurethane-based DEB catheters generated USD 225.4 million in revenue in 2024 and are expected to grow at a CAGR of 10.4% through 2034. Known for its flexibility, biocompatibility, and durability, polyurethane is ideal for navigating complex vascular structures, ensuring patient comfort, and reducing the risk of injury during procedures.

Hospitals and clinics accounted for the largest share of the market in 2024, driven by increasing admissions for cardiovascular and peripheral artery disorders. The segment is expected to reach USD 938.3 million by 2034, supported by the growing demand for advanced surgical care and minimally invasive interventions.

In terms of regional performance, North America dominated the market with USD 272.2 million in revenue in 2024. This growth is attributed to the region's advanced healthcare infrastructure, high prevalence of CVDs, and widespread adoption of DEB technology in interventional cardiology and vascular care.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of peripheral and cardiovascular diseases
    • 3.2.1.2 Technological advancements in drug-eluting balloon catheters
    • 3.2.1.3 Increasing preference for minimally invasive procedures
    • 3.2.1.4 Rising geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of product
    • 3.2.2.2 Risk of infection associated with the use of drug-eluting balloon catheters
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Coronary artery disease drug-eluting balloon catheters
  • 5.2.1 Paclitaxel
  • 5.2.2 Sirolimus
• 5.3 Peripheral vascular disease drug-eluting balloon catheters
  • 5.3.1 Paclitaxel
  • 5.3.2 Sirolimus

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Polyurethane
• 6.3 Nylon
• 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory surgical centers
• 7.4 Catheterization laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aachen Resonance GmbH
• 9.2 B. Braun
• 9.3 Becton, Dickinson and Company
• 9.4 Biosensors International
• 9.5 Biotronik AG
• 9.6 Boston Scientific Corporation
• 9.7 Eurocor GmbH
• 9.8 iVascular S.L.U.
• 9.9 Zhejiang Barty Medical Technology Co.Ltd
• 9.10 Lepu Medical Technology(Beijing) Co. Ltd.
• 9.11 MedAlliance
• 9.12 Medtronic plc